Levels of serum copeptin in preeclampsia and association with maternal echocardiographic and doppler ultrasound parameters

Abstract

Copeptin is a peptide, which has been reported as a valuable tool in the monitoring of major cardiovascular diseases such as myocardial infarction and heart failure. Echographic examinations are useful in assessment of alterations in cardiovascular structure and function during pregnancy. Having in mind the role of copeptin in the cardiovascular abnormalities and the subtle changes in heart and spiral arteries which can be detected by echography, the aim of the present study was to evaluate copeptin concentrations in preeclampsia (PE) and to investigate the existence of association between copeptin and maternal echocardiographic and Doppler ultrasound parameters. The current research was a case-control study. Fifty-five women with PE were examined. The mean age of patients was 24.9±6 years; and the mean age of the control group of 35 women with normal pregnancies was 24.7±5.4 years. The enzyme-linked immunosorbent assay (ELISA) was used to determine concentrations of copeptin. Echocardiographic assessment of all subjects was performed. In addition, uterine (UtA) artery pulsatility indices (PI) were evaluated. Levels of serum copeptin in preeclamptic women were statistically insignificantly lower than these in women with normal pregnancy: 142.2 (131.4÷146.7) vs. 144.8 (138.5÷ 149.4) ng/l (p>0.05). Copeptin correlated with systolic blood pressure (r=-0.41; p=0.0001), diastolic blood pressure (r=-0.30; p=0.004), UtA PI (r=-0.36; p=0.0005), IVS (r=-0.23; p=0.03) and LVPWD (r=-0.21; p=0.05). We report the existence of a relationship between serum copeptin and maternal echocardiographic and Doppler ultrasound parameters in preeclampsia. The present study give arguments for a potential copeptin implication on maternal cardiac structures and spiral arteries. Our results also confirm that copeptin is associated with increase of blood pressure in preeclampsia.

Keywords

• copeptin
• blood pressure
• echography
• preeclampsia
• serum levels

References

1. 1. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013 Nov;122(5):1122-1131.
2. 2. Eiland E, Nzerue C, Faulkner M. Preeclampsia 2012. J Pregnancy. Jul 11 2012; 586578.
3. 3. Goldman-Wohl DS, Yagel S. Examination of distinct fetal and maternal molecular pathways suggests a mechanism for the development of preeclampsia. J Reprod Immunol. 2007; 76: 54–60.
4. 4. Dias-Junior CA, Chen J, Cui N. Angiogenic imbalance and diminished matrix metalloproteinase-2 and -9 underlie regional decreases in uteroplacental vascularization and feto-placental growth in hypertensive pregnancy. Biochem Pharmacol. 2017; 146: 101–116.
5. 5. Robertson GL, Mahr EA, Athar S, Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest.1973; 52(9): 2340–52.
6. 6. Gaggin HK, Januzzi JL. Cardiac Biomarkers and Heart Failure. Expert Analysis. Latest in Cardiology. J Am Coll Cardiol. Feb 10 2015: https://www.acc.org/%2Flatest-in-cardiology%2Farticles%2F2015%2F02%2F09%2F13%2F00%2Fcardiac-biomarkers-and-heart-failure.
7. 7. Land H, Schütz G, Schmale H, Richter D. Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor. Nature.1982; 295(5847): 299–303.
8. 8. Acher R, Chauvet J, Rouille Y. Dynamic processing of neuropeptides: sequential conformation shaping of neurohypophysialpreprohormones during intraneuronal secretory transport. J Mol Neurosci.2002; 18(3): 223–8.

9. 9. Repaske DR, Medlej R, Gültekin EK, Krishnamani MR, Halaby G, Findling JW, et al. Heterogeneity in clinical manifestation of autosomal dominant neurohypophyseal diabetes insipidus caused by a mutation encoding Ala-1-->Val in the signal peptide of the arginine vasopressin/neurophysin II/copeptin precursor. J Clin Endocrinol Metab. 1997 Jan;82(1):51-6.
10. 10. Morgenthaler NG, Struck J, Jochberger S, Dünser MW. Copeptin: clinical use of a new biomarker. Trends Endocrin Met.2008; 19(2): 43–9.
11. 11. Düngen HD, Tscholl V, Obradovic D, Radenovic S, Matic D, Musial Bright L, et al. Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study. ESC Heart Fail. 2018 Apr;5(2):288-296.
12. 12. Preibisz JJ, Sealey JE, Laragh JH, Cody RJ, Weksler BB. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension. 1983 Mar-Apr;5(2 Pt 2):I129-38.
13. 13. Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation.2007; 115 (16): 2103–10.
14. 14. Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol.2009; 54 (1): 60–8.
15. 15. Acher R, Chauvet J, Rouille Y. Dynamic processing of neuropeptides: sequential conformation shaping of neurohypophysialpreprohormones during intraneuronal secretory transport". J Mol Neurosci. 2002; 18(3): 223–8.
16. 16. Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda FM, et al. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol. 2010; 55(19): 2096–106.
17. 17. Maisel A, Mueller C, Neath SX, Christenson RH, Morgenthaler NG, McCord J, et al. Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction). J Am Coll Cardiol. 2013; 62(2): 150–160.
18. 18. Boeckel JN, Oppermann J, Anadol R, Fichtlscherer S, Zeiher AM, Keller T. Analyzing the Release of Copeptin from the Heart in Acute Myocardial Infarction Using a Transcoronary Gradient Model. Sci Rep. 2016; 6: 20812.
19. 19. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991; 115: 343–349.
20. 20. Shah SJ, Thenappan T, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Association of serum creatinine with abnormalhemodynamics and mortality in pulmonary arterial hypertension. Circulation.2008; 117: 2475–2483.
21. 21. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: Insights from the Registry to Evaluate Early andLong-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation.2010; 122: 164–172.
22. 22. Reddy M, Wright L, Rolnik DL, Li W, Mol BW, La Gerche A, et al. Evaluation of Cardiac Function in Women With a History of Preeclampsia: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2019 Nov 19;8(22):e013545.
23. 23. Castleman JS, Ganapathy R, Taki F, Lip GY, Steeds RP, Kotecha D. Echocardiographic Structure and Function in Hypertensive Disorders of Pregnancy: A Systematic Review. Circ Cardiovasc Imaging. 2016 Sep;9(9):e004888.
24. 24. Liu S, Elkayam U, Naqvi TZ. Echocardiography in Pregnancy: Part 1. Curr Cardiol Rep. 2016 Sep;18(9):92.
25. 25. Rubler S, Damani PM, Pinto ER. Cardiac size and performance during pregnancy estimated with echocardiography. Am J Cardiol. 1977; 40(4): 534-540.
26. 26. Giordano R, Cacciatore A, Romano M, La Rosa B, Fonti I, Vigna R. Uterine artery Doppler flow studies in obstetric practice. J Prenat Med. 2010;4(4):59-62.
27. 27. Papageorghiou AT, Yu CK, Erasmus IE, Cuckle HS, Nicolaides KH. Assessment of risk for the development of pre-eclampsia by maternal characteristics and uterine artery Doppler. BJOG.2005;112:703–9.
28. 28. Marsál K. Rational use of Doppler ultrasound in perinatal medicine. J Perinat Med. 1994; 22(6): 463-74.
29. 29. Maulik D, Mundy D, Heitmann E, Maulik D. Evidence-based approach to umbilical artery Doppler fetal surveillance in high-risk pregnancies: an update. Clin Obstet Gynecol. 2010;53 (4): 869-78.
30. 30. Coppens M, Loquet P, Kollen M, De Neubourg F, Buytaert P. Longitudinal evaluation of uteroplacental and umbilical blood flow changes in normal early pregnancy. Ultrasound Obstet Gynecol. 1996 Feb;7(2):114-21.
31. 31. Acharya G, Wilsgaard T, Berntsen GK, Maltau JM, Kiserud T. Reference ranges for serial measurements of umbilical artery Doppler indices in the second half of pregnancy. Am J Obstet Gynecol. 2005; 192 (3): 937-44. doi:10.1016/j.ajog.2004.09.019.
32. 32. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, et al; ESC Scientific Document GroupEuropean Society of Cardiology (ESC) Guideline for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018; 39(34): 3165–3241.
33. 33. Marwick TH, Gillebert TC, Aurigemma G, Chirinos J, Derumeaux G, Galderisi M, et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). Eur Heart J Cardiovasc Imaging. 2015; 16(6): 577–605.
34. 34. Bhide A, Acharya G, Bilardo CM, Brezinka C, Cafici D, Hernandez-Andrade E, et al. ISUOG Practice Guidelines: use of Doppler ultrasonography in obstetrics. Ultrasound Obstet Gynecol. 2013; 41: 233-239. https://doi.org/10.1002/uog.12371
35. 35. Dennis AT. Transthoracic echocardiography in women with preeclampsia, Curr Opin Anaesthesiol. 2015; 28(3): 254-260.
36. 36. Dennis AT, Castro JM. Transthoracic echocardiography in women with treated severe pre-eclampsia. Anaesthesia. 2014; 69(5): 436-444.
37. 37. Dennis AT, Castro JM. Echocardiographic differences between preeclampsia and peripartum cardiomyopathy. Int J Obstet Anesth. 2014; 23(3): 260-266.
38. 38. Dennis AT, Castro J, Carr C, Simmons S, Permezel M, Royse C. Haemodynamics in women with untreated pre-eclampsia. Anaesthesia. 2012; 67(10): 1105-1118.
39. 39. Melchiorre K, Sutherland GR, Baltabaeva A, Liberati M, Thilaganathan B. Maternal cardiac dysfunction and remodeling in women with preeclampsia at term. Hypertension. 2011; 57(1): 85-93.
40. 40. Kyung Choi S, Chul Shin J, Gyu Park Y, Yang Park I, Young Kwon J, Sun Ko H, et al. The efficacy of peripartum transthoracic echocardiography in women with preeclampsia. Pregnancy Hypertens.2017 Oct;10:187-191.
41. 41. Ghossein-Doha C, Peeters L, van Heijster S, van Kuijk S, Spaan J, Delhaas T, et al. Hypertension after preeclampsia is preceded by changes in cardiac structure and function. Hypertension. 2013; 62(2): 382-390.
42. 42. Parizadeh SM, Ghandehari M, Parizadeh MR, Ferns GA, Ghayour-Mobarhan M, Avan A, et al. The diagnostic and prognostic value of copeptin in cardiovascular disease, current status, and prospective. J Cell Biochem. 2018 Nov;119(10):7913-7923.
43. 43. Lattuca B, Sy V, Nguyen LS, Bernard M, Zeitouni M, Overtchouk P, et al. Copeptin as a prognostic biomarker in acute myocardial infarction. Int J Cardiol. 2019 Jan 1;274:337-341.
44. 44. Rouleau JL, de Champlain J, Klein M, Bichet D, Moyé L, Packer M, et al. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol. 1993; 22(2): 390–8.
45. 45. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA.2007; 297(12): 1332–43.
46. 46. Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol. 2008; 52(4): 266–72.
47. 47. Yeung EH, Liu A, Mills JL, Zhang C, Männistö T, Lu Z, et al. Increased levels of copeptin before clinical diagnosis of preeclampsia. Hypertension. 2014 Dec;64(6):1362-7.
48. 48. Akinlade KS, Adediji IO, Rahamon SK, Fawole AO, Tongo OO. Serum copeptin and pregnancy outcome in preeclampsia. Niger Med J. 2015 Sep-Oct;56(5):362-8.
49. 49. Tuten A, Oncul M, Kucur M, Imamoglu M, Ekmekci OB, Acıkgoz AS, et al. Maternal serum copeptin concentrations in early- and late-onset pre-eclampsia. Taiwan J Obstet Gynecol. 2015 Aug;54(4):350-4.
50. 50. Zulfikaroglu E, Islimye M, Tonguc EA, Payasli A, Isman F, Var T, et al. Circulating levels of copeptin, a novel biomarker in pre-eclampsia. J Obstet Gynaecol Res. 2011 Sep;37(9):1198-202.
51. 51. Santillan MK, Santillan DA, Scroggins SM, Min JY, Sandgren JA, Pearson NA, et al. Vasopressin in preeclampsia: a novel very early human pregnancy biomarker and clinically relevant mouse model. Hypertension. 2014 Oct;64(4):852-9.
52. 52. Hagras AM, Hesham M. El-Tokhy. Maternal Serum Copeptin for Early Prediction of Preeclampsia. Med J Cairo Univ. 2018; 86(March): 933-937.
53. 53. Mohamed OS, Eldesoky NAR, Younis NF, El-Mandoury Ahmed AA. Copeptin in Pregnancy Induced Hypertension and Pre-eclamptic Egyptian Women: Relation with CD62p; Case Control Study Res in Obstet Gynecol. 2018; 6(2): 23-31.